Our findings also suggest the possibility of targeting the TRIM71–mtp53 axis as a potential strategy for future development of anticancer therapies for mtp53-expressed ovarian carcinomas and perhaps other types of cancers that harbor mtp53s. Here, TRIM71 is linked to cancer.